Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naquotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 10/20 | 1.00 |
| ▸ | RET | P07949 | 9/20 | 0.62 |
| ▸ | ROS1 | P08922 | 9/20 | 0.62 |
| ▸ | FLT3 | P36888 | 9/20 | 0.62 |
| ▸ | EML4 | Q9HC35 | 8/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.62 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | CIT | O14578 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | BUB1 | O43683 | 1/20 | 0.51 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.51 |
| ▸ | STK16 | O75716 | 1/20 | 0.51 |
| ▸ | STK10 | O94804 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | LATS1 | O95835 | 1/20 | 0.51 |
| ▸ | SLC25A5 | P05141 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naquotinib SCHEMBL16196078 | 1.00 | EGFR (1.00) | EGFRRETROS1FLT3EML4 | |
| Naquotinib SCHEMBL19921009 | 1.00 | EGFR (1.00) | EGFRRETROS1FLT3EML4 | |
| Naquotinib SCHEMBL29409491 | 0.97 | EGFR (0.95) | EGFRRETROS1FLT3EML4 | |
| Naquotinib SCHEMBL18687011 | 0.97 | EGFR (0.95) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16195821 | 0.96 | EGFR (1.00) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16207133 | 0.96 | EGFR (0.93) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16196142 | 0.94 | EGFR (0.89) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16207004 | 0.94 | EGFR (0.89) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16258225 | 0.94 | EGFR (0.89) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16207170 | 0.93 | EGFR (0.87) | EGFRRETROS1FLT3EML4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 906 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070138-A | Compositions and methods for expressing EGFR | 瑞普利科特生物科学公司 | 2026-05-19 | — | — | CN | claimed |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | UNIV NEW YORK (US) | 2025-11-20 | — | — | US | claimed |
| EP-4633630-A1 | TREATMENT OF CANCER RESISTANT TO EGFR TKI USING C-MET INHIBITOR | Apollomics Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250188171-A1 | COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND CMET | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | claimed |
| US-20250179193-A1 | TREATMENT WITH AN ANTIBODY THAT BINDS EGFR AND CMET | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-05 | — | — | US | claimed |
| CN-120078896-A | Combination therapy comprising antibodies that bind EGFR to cMET | 美勒斯公司 | 2025-06-03 | — | — | CN | claimed |
| CN-120091813-A | Combination therapy for the treatment of abnormal cell growth | 维瑞斯特姆股份有限公司 | 2025-06-03 | — | — | CN | claimed |
| CN-120058955-A | Treatment with antibodies that bind EGFR and cMET | 美勒斯公司 | 2025-05-30 | — | — | CN | claimed |
| WO-2025105961-A1 | COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND cMET. | MERUS N.V. (NL) | 2025-05-22 | — | — | WO | claimed |
| US-11286264-B2 | Macrocyclic compounds and uses thereof | Turning Point Therapeutics, Inc. (US) | 2022-03-29 | — | — | US | claimed |
| US-11285154-B2 | Methods and compositions for treating cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-03-29 | — | — | US | claimed |
| CN-110325212-B | Farnesyl transferase inhibitors for use in methods of treating cancer | 库拉肿瘤学公司 | 2022-03-22 | — | — | CN | claimed |
| EP-3965896-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | The United States Government as Represented by the Department of Veterans Affairs (US) | 2022-03-16 | — | — | EP | claimed |
| WO-2022045976-A1 | METHOD OF MODULATING SENSITIVITY TO TYROSINE KINASE INHIBITOR | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2022-03-03 | — | — | WO | claimed |
| CN-114099514-A | Methods for preventing or treating side effects associated with EGFR dysfunction | 上海岸阔医药科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| EP-3956035-A1 | COMPOUNDS AGAINST CANCER BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS | Board of Regents, The University of Texas System (US) | 2022-02-23 | — | — | EP | claimed |
| EP-3955928-A1 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS | Board of Regents, The University of Texas System (US) | 2022-02-23 | — | — | EP | claimed |
| CN-113993592-A | Compounds against cancers bearing tyrosine kinase inhibitor resistant EGFR mutations | 得克萨斯大学体系董事会 | 2022-01-28 | — | — | CN | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286264-B2 | Macrocyclic compounds and uses thereof | CSF3R, CSF1R, FLT3 | EGFR 31/4885RET 7/4885ROS1 19/4885 |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | MICA, CD74, HLA-DRB1 | EGFR 2295/4885RET 2779/4885ROS1 4638/4885 |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | KRAS, NRAS, HRAS | EGFR 24/4885RET 57/4885ROS1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.